Evidence map›Paper›PMID 35858291›Full record

ArticleBlood advances2022

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.

Armin Ghobadi, Jack H Landmann, Alun Carter, Matthew L Cooper, Mehmet Emrah Selli, Jufang Chang, Matthew Baker, Christopher A Miller, Francesca Ferraro, David Y Chen and 13 more

Abstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Armin GhobadiDivision of Oncology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0001-8848-8474
Jack H LandmannDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Alun CarterDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Matthew L CooperDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Mehmet Emrah SelliDivision of Oncology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-3478-8970
Jufang ChangDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Matthew BakerThe University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0001-9039-8523
Christopher A MillerDivision of Oncology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0003-4266-6700
Francesca FerraroDivision of Oncology, Washington University School of Medicine, St Louis, MO.
David Y ChenDivision of Oncology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-3681-6576
Amanda M SmithDivision of Oncology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-8716-6745
Taylor A LaValleDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Eric J DuncavageDivision of Oncology, Washington University School of Medicine, St Louis, MO.
Justin ChouKite, a Gilead Company, Santa Monica, CA.
Victor TamKite, a Gilead Company, Santa Monica, CA.
Joseph M BenounKite, a Gilead Company, Santa Monica, CA.
Jenny NaterKite, a Gilead Company, Santa Monica, CA.ORCID 0000-0001-9495-0653
Nathalie SchollerKite, a Gilead Company, Santa Monica, CA.
Francesca MillettiKite, a Gilead Company, Santa Monica, CA.
Remus VezanKite, a Gilead Company, Santa Monica, CA.
Adrian BotKite, a Gilead Company, Santa Monica, CA.
John M RossiKite, a Gilead Company, Santa Monica, CA.
Nathan SinghDivision of Oncology, Washington University School of Medicine, St Louis, MO.

Funding

COMPREHENSIVE INFORMATIC ANALYSES OF AML GENOMES AND EPIGENOMESR50CA211782 · NCI · WASHINGTON UNIVERSITY · PI Christopher A Miller · 2017 to 2026
$1.5M
NCI NIH HHS R50 CA211782
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CD19ImmunotherapyGenomicsAntigens, CD19

Identifiers

PMID35858291
PMCPMC9582720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.